4.6 Article

Impact of a multifaceted prevention program on ventilator-associated pneumonia including selective oropharyngeal decontamination

Journal

INTENSIVE CARE MEDICINE
Volume 44, Issue 11, Pages 1777-1786

Publisher

SPRINGER
DOI: 10.1007/s00134-018-5227-4

Keywords

Ventilator-associated pneumonia; Multimodal strategy; Selective oropharyngeal decontamination; Intensive care unit

Funding

  1. Department of Anesthesiology, Intensive Care, and Pharmacology, University Hospitals of Geneva, Switzerland

Ask authors/readers for more resources

PurposeWe describe the impact of a multifaceted program for decreasing ventilator-associated pneumonia (VAP) after implementing nine preventive measures, including selective oropharyngeal decontamination (SOD).MethodsWe compared VAP rates during an 8-month pre-intervention period, a 12-month intervention period, and an 11-month post-intervention period in a cohort of patients who received mechanical ventilation (MV) for>48h. The primary objective was to assess the effect on first VAP occurrence, using a Cox cause-specific proportional hazards model. Secondary objectives included the impact on emergence of antimicrobial resistance, antibiotic consumption, duration of MV, and ICU mortality.ResultsPre-intervention, intervention and post-intervention VAP rates were 24.0, 11.0 and 3.9 VAP episodes per 1000 ventilation-days, respectively. VAP rates decreased by 56% [hazard ratio (HR) 0.44, 95% CI 0.29-0.65; P<0.001] in the intervention and by 85% (HR 0.15, 95% CI 0.08-0.27; P<0.001) in the post-intervention periods. During the intervention period, VAP rates decreased by 42% (HR 0.58, 95% CI 0.38-0.87; P<0.001) after implementation of eight preventive measures without SOD, and by 70% after adding SOD (HR 0.30, 95% CI 0.13-0.72; P<0.001) compared to the pre-intervention period. The incidence density of intrinsically resistant bacteria (to colistin or tobramycin) did not increase. We documented a significant reduction of days of therapy per 1000 patient-days of broad-spectrum antibiotic used to treat lower respiratory tract infection (P<0.028), median duration of MV (from 7.1 to 6.4days; P<0.003) and ICU mortality (from 16.2 to 13.5%; P<0.049) for patients ventilated>48h between the pre- and post-intervention periods.ConclusionsOur preventive program produced a sustained decrease in VAP incidence. SOD provides an additive value.

Authors

I am an author on this paper
Click your name to claim this paper and add it to your profile.

Reviews

Primary Rating

4.6
Not enough ratings

Secondary Ratings

Novelty
-
Significance
-
Scientific rigor
-
Rate this paper

Recommended

No Data Available
No Data Available